Viral Disease Diagnosis Market Overview
The report is titled as ‘Viral Disease Diagnosis Market: Opportunity Analysis and Future Assessment 2022-2030’. An overview of conceptual frameworks, analytical approaches of the Viral Disease Diagnosis market is the main objective of the report, which further consists the market opportunity and insights of the data involved in the making of the respective market. Viral Disease Diagnosis market is expected to grow with significant rate in the near future.
The viral disease diagnosis market is estimated to reach at a value of US$ 18,560.5 Mn by the end of 2022 and expected to reach at a value of US$ 30,046.1 Mn by 2030 with a significant CAGR of 6.2%.
Viral Disease Diagnosis Introduction
Viruses or infectious substances can be perceived as extremely tiny or minute organisms that are composed of genetic material and have the potential to induce infection into the human body. These viruses trespass, occupy and attach themselves to a host cell, thus terminating or changing the function of that cell. As a result, such activity causes an infection in the human body. Notably, there are a number of ways by which viruses can be transported, for instance, any kind of contact with an already infected person, or unsafe intercourse. The inadequate personal hygiene is also likely to increase the chances of virus infection.
Viral disease diagnosis is an extremely essential step to mitigate the odds of epidemics and in order to provide treatment at the right time. The heavy load of viral diseases among the population persists to be a general concern across communities all around the world, majorly after the Covid-19 global pandemic. Having said that, the sudden outbreak of Covid-19 global crisis positively influenced the global viral disease diagnosis market. In order to support that, in accordance with the World Health Organization, as of 24th February 2022, there were roughly around 428,511,601 confirmed cases of COVID-19 infection across the world. Though diagnostics for SARS-CoV-2 screening are being developed in a constant manner in order to cater to the needs of markets with exclusive regulatory constraints
Advances in clinical research and molecular diagnostic technology is expected to drive the viral molecular diagnosis market
The primary challenge for virus detection changes in the viral genome. As a result, diagnosis becomes more difficult. As a result, new microarray techniques and rapid tests are emerging. Increased research and development for virus detection are expected to drive global virological diagnosis. According to the WHO, 1.5 million new infections occur worldwide each year. This increase in infection rates will directly benefit the viral diagnostic market.
Furthermore, with the reduction of detection time and the selection of effective treatment methods, the development of rapid and accurate detection and testing has aided market growth. Furthermore, the increased awareness of viral infections and the availability of diagnostic tests for viral infectious diseases are expected to drive the viral molecular diagnostics market.
Key Takeaways from the Market Study
Viral Disease Diagnosis Market Segmentation
The global viral disease diagnosis market is segmented on the basis of technique, product, virus type, end use, and region
By Technique
Polymerase Chain Reaction (PCR)
Rapid Antigen Detection Tests (RADTs)
Multiplex PCR
Real-Time PCR
Reverse Transcription-PCR (RT-PCR)
Nested-PCR
By Product
Instruments
Services & Software
By Virus Type
SARS-CoV
Respiratory syncytial virus (RSV)
Influenza viruses.
hepatitis C virus
hepatitis B virus
hepatitis A virus
Influenza A and Influenza B viruses
By End-Use
Diagnostic Centres
Nursing homes
Hospitals
Clinics
Laboratories
By Region
North America
Latin America
Asia Pacific
Europe
Middle East
Africa
Viral Disease Diagnosis Market Key Players
Some of the key participating players in global Viral Disease Diagnosis market are:
Adaltis S.r.l
R-Biopharm AG
Siemens Healthcare Private Limited
Toronto Bioscience
Merck KGaA
Abbott Laboratories
BioMérieux SA
Cepheid
Epitope Diagnostics Inc.
F. Hoffmann-La Roche Ltd
Becton Dickinson and Company
Factors that are benchmarked while estimating the market
Various factors that are benchmarked while estimating the market growth includes (but not restricted to):
Global Healthcare Industry Outlook
Medical Treatment Growth Outlook
Requirement for Viral testing and treatment
Concerns for growing viral infections
Top Companies Historical Growth Rate
Pricing Impact
Impact of Regulations
Growth in investment in healthcare sector
Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to take informed decision.
A mix of top-down and bottom-up approach is followed to arrive and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, it’s product sales, previous growth rates and market expansion plans are considered to generate market share in the market.
To learn more about this report, request a free sample copy
The viral disease diagnosis market is estimated to reach at a value of US$ 18,560.5 Mn by the end of 2022 and expected to reach at a value of US$ 30,046.1 Mn by 2030 with a significant CAGR of 6.2%.
The base year for the report is 2021 in viral disease diagnosis market.
The global viral disease diagnosis market is segmented on the basis of technique, product, virus type, end use, and region
Some of the key participating players in global Viral Disease Diagnosis market are Thermo Fisher Scientific, Adaltis S.r.l, R-Biopharm AG, Siemens Healthcare Private Limited, Toronto Bioscience, Merck KGaA, Abbott Laboratories, BioMérieux SA, Cepheid, Epitope Diagnostics Inc., F. Hoffmann-La Roche Ltd, and Becton Dickinson and Company